» Articles » PMID: 39091166

Impact of COVID-19 on Human Immunodeficiency Virus Tests, New Diagnoses, and Healthcare Visits in the Republic of Korea: a Retrospective Study from 2016 to 2021

Overview
Specialty Public Health
Date 2024 Aug 2
PMID 39091166
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Public health workers have been at the forefront of treating patients with coronavirus disease 2019 (COVID-19) and managing the pandemic. The redeployment of this workforce has limited or interrupted other public health services, including testing for human immunodeficiency virus (HIV). This study aims to examine the impact of COVID-19 on HIV testing and diagnosis in the Republic of Korea from 2016 to 2021, comparing data before and after the onset of COVID-19.

Methods: Annual HIV testing data were collected from each institution through direct communication or from open-source databases. The annual number of new HIV cases was obtained from the official report of the Korea Disease Control and Prevention Agency. Data on healthcare visits for HIV diagnosis or treatment were extracted from the open-source database of the National Insurance Health Service of Korea. Interrupted time series regression was conducted, stratified by institution type.

Results: In 2020, HIV tests, diagnoses, and visits decreased. Notably, public health centers experienced a substantial reduction in 2020-2021 compared to previous years. The annual percentage change in HIV tests was -53.0%, while for HIV diagnoses, it was -31.6%. The decrease in visits for HIV was also most pronounced for public facilities: -33.3% in 2020 and -45.6% in 2021 relative to 2019.

Conclusion: The numbers of tests, diagnoses, and healthcare visits for HIV at public health centers in the Republic of Korea substantially decreased in 2020 and 2021. The impacts of these changes on the early diagnosis and treatment of HIV necessitate further monitoring.

Citing Articles

Epidemiological Characteristics of HIV-Infected Individuals by the Registration for Special Exempted Calculation: A Nationwide Cohort Study.

Choi Y, Ahn K, Kim S, Choi B, Choi J, Kim J Infect Chemother. 2025; 56(4):510-521.

PMID: 39762927 PMC: 11704859. DOI: 10.3947/ic.2024.0085.

References
1.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

2.
. Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea. Osong Public Health Res Perspect. 2020; 11(1):8-14. PMC: 7045878. DOI: 10.24171/j.phrp.2020.11.1.03. View

3.
Wagner A, Soumerai S, Zhang F, Ross-Degnan D . Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002; 27(4):299-309. DOI: 10.1046/j.1365-2710.2002.00430.x. View

4.
Nitpolprasert C, Anand T, Phanuphak N, Reiss P, Ananworanich J, Peay H . A qualitative study of the impact of coronavirus disease (COVID-19) on psychological and financial wellbeing and engagement in care among men who have sex with men living with HIV in Thailand. HIV Med. 2021; 23(3):227-236. PMC: 8653254. DOI: 10.1111/hiv.13190. View

5.
. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin Infect Dis. 2020; 73(7):e2005-e2015. PMC: 7499501. DOI: 10.1093/cid/ciaa1198. View